Symbols / GTBP Stock $0.31 -12.93% GT Biopharma, Inc.

Healthcare • Biotechnology • United States • NCM
GTBP (Stock) Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
Stock Fundamentals
Scroll to Statements
Index EQUITY
Sector Healthcare
Industry Biotechnology
CEO Mr. Michael Martin Breen L.L.B.
Exch · Country NCM · United States
Market Cap 9.86M
Enterprise Value 4.51M
Income -34.45M
Sales —
FCF (ttm) -12.01M
Book/sh 0.23
Cash/sh 0.22
Employees 1
Insider 10d —
IPO Mar 27, 2018
Div forward ($/yr)
Div TTM ($/yr)
Dividend Yield
Ex-Div Date
5Y Avg Yield
Yield vs 5Y Avg
Payout 0.00%
P/E —
Forward P/E -0.03
PEG 1.05
P/S —
P/B 1.38
P/C —
EV/EBITDA —
EV/Sales —
Quick Ratio 2.94
Current Ratio 3.50
Debt/Eq —
LT Debt/Eq —
EPS (ttm) -5.81
EPS next Y -10.80
EPS Growth —
Revenue Growth —
EPS Gr Q/Q —
Rev Gr Q/Q —
Earnings (next) 2026-03-02
Earnings (prior) 2026-03-02
ROA -125.85%
ROE -13.77%
ROIC —
Gross Margin 0.00%
Oper. Margin 0.00%
Profit Margin 0.00%
Shs Outstand 31.55M
Shs Float 30.83M
Insider Own 3.91%
Instit Own 4.40%
Short Float 2.37%
Short Ratio 1.17
Short Interest 747.38K
52W High 3.85
vs 52W High -91.88%
52W Low 0.31
vs 52W Low 0.00%
Beta 1.20
Impl. Vol. —
Rel Volume 1.64
Avg Volume 882.92K
Volume 1.44M
Target (mean) $3.00
Tgt Median $3.00
Tgt Low $3.00
Tgt High $3.00
# Analysts 1
Recom None
Prev Close $0.36
Price $0.31
Change -12.93%
About

GT Biopharma, Inc., a clinical stage biopharmaceutical company, engages in the development and commercialization of immuno-oncology products based on its Tri-specific Killer Engager (TriKE) and Tetra-specific Killer Engager (Dual Targeting TriKE) platforms. It develops GTB-3650, which is in phase 1 trials that target CD33 on the surface of myeloid leukemias and an agonistic camelid; GTB-5550, that is in phase 1 dose escalation basket trial that targets B7-H3 on the surface of advanced solid tumors;and GTB-7550, a pre-clinical stage product candidate in development for the treatment of lupus and other autoimmune disorders. The company was formerly known as OXIS International, Inc. and changed its name to GT Biopharma, Inc. in July 2017. GT Biopharma, Inc. was incorporated in 1965 and is based in San Francisco, California.

Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$3.00
Mean price target
2. Current target
$0.31
Latest analyst target
3. DCF / Fair value
$-6.85
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$0.31
Low
$3.00
High
$3.00
Mean
$3.00

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2024-12-02 init Roth MKM — → Buy $11
News
RSS: Latest GTBP news
Insider Transactions

No recent insider transactions.

Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
0.00
0.00
0.00
0.00
Operating Revenue
0.00
0.00
0.00
0.00
Operating Expense
12.42
-13.52%
14.36
+5.80%
13.58
-36.13%
21.26
Research And Development
3.47
-40.12%
5.80
-10.33%
6.47
-26.61%
8.81
Selling General And Administration
8.95
+4.48%
8.57
+20.48%
7.11
-42.87%
12.45
General And Administrative Expense
—
—
—
—
Other Gand A
—
—
—
—
Total Expenses
12.42
-13.52%
14.36
+5.80%
13.58
-36.13%
21.26
Operating Income
-12.42
+13.52%
-14.36
-5.80%
-13.58
+36.13%
-21.26
Total Operating Income As Reported
-12.42
+13.52%
-14.36
-5.80%
-13.58
+36.13%
-21.26
EBITDA
-28.23
-114.46%
-13.16
-78.25%
-7.38
+64.63%
-20.88
Normalized EBITDA
-0.73
+94.77%
-13.96
-9.28%
-12.78
+39.06%
-20.96
EBIT
-28.23
-114.46%
-13.16
-78.25%
-7.38
+64.63%
-20.88
Total Unusual Items
-27.50
-3537.13%
0.80
-85.16%
5.39
+5958.43%
0.09
Total Unusual Items Excluding Goodwill
-27.50
-3537.13%
0.80
-85.16%
5.39
+5958.43%
0.09
Special Income Charges
-27.74
0.00
-100.00%
0.55
0.00
Other Special Charges
27.74
—
-0.55
—
Net Income
-28.35
-115.42%
-13.16
-73.25%
-7.60
+63.62%
-20.88
Pretax Income
-28.35
-115.42%
-13.16
-73.25%
-7.60
+63.62%
-20.88
Net Non Operating Interest Income Expense
-0.00
-101.00%
0.40
-29.10%
0.57
+99.65%
0.28
Interest Expense Non Operating
0.13
0.00
-100.00%
0.21
+2562.50%
0.01
Net Interest Income
-0.00
-101.00%
0.40
-29.10%
0.57
+99.65%
0.28
Interest Expense
0.13
0.00
-100.00%
0.21
+2562.50%
0.01
Interest Income Non Operating
0.12
-69.40%
0.40
-48.46%
0.78
+167.12%
0.29
Interest Income
0.12
-69.40%
0.40
-48.46%
0.78
+167.12%
0.29
Other Income Expense
-15.93
-2091.00%
0.80
-85.22%
5.41
+5980.90%
0.09
Other Non Operating Income Expenses
11.57
—
0.02
—
Gain On Sale Of Security
0.24
-69.88%
0.80
-83.49%
4.84
+5343.82%
0.09
Tax Rate For Calcs
0.00
0.00
0.00
0.00
Tax Effect Of Unusual Items
0.00
0.00
0.00
0.00
Net Income Including Noncontrolling Interests
-28.35
-115.42%
-13.16
-73.25%
-7.60
+63.62%
-20.88
Net Income From Continuing Operation Net Minority Interest
-28.35
-115.42%
-13.16
-73.25%
-7.60
+63.62%
-20.88
Net Income From Continuing And Discontinued Operation
-28.35
-115.42%
-13.16
-73.25%
-7.60
+63.62%
-20.88
Net Income Continuous Operations
-28.35
-115.42%
-13.16
-73.25%
-7.60
+63.62%
-20.88
Normalized Income
-0.86
+93.86%
-13.96
-7.49%
-12.99
+38.07%
-20.97
Net Income Common Stockholders
-34.45
-161.73%
-13.16
-73.25%
-7.60
+63.62%
-20.88
Otherunder Preferred Stock Dividend
5.78
0.00
—
—
Diluted EPS
—
-6.94
-23.05%
-5.64
+71.02%
-19.46
Basic EPS
—
-6.94
-23.05%
-5.64
+71.02%
-19.46
Basic Average Shares
—
1.90
+40.78%
1.35
+25.60%
1.07
Diluted Average Shares
—
1.90
+40.78%
1.35
+25.60%
1.07
Diluted NI Availto Com Stockholders
-34.45
-161.73%
-13.16
-73.25%
-7.60
+63.62%
-20.88
Preferred Stock Dividends
0.32
—
—
—
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Assets
8.11
+91.54%
4.23
-70.00%
14.11
-15.70%
16.74
Current Assets
8.11
+91.54%
4.23
-69.89%
14.06
-15.13%
16.56
Cash Cash Equivalents And Short Term Investments
6.81
+72.39%
3.95
-71.72%
13.97
-15.36%
16.51
Cash And Cash Equivalents
6.81
+72.39%
3.95
+266.17%
1.08
-80.98%
5.67
Other Short Term Investments
—
0.00
-100.00%
12.89
+18.98%
10.84
Prepaid Assets
—
—
—
—
Current Deferred Assets
0.63
0.00
—
—
Restricted Cash
0.09
+1.08%
0.09
0.00
—
Other Current Assets
0.57
+201.60%
0.19
+123.81%
0.08
+55.56%
0.05
Total Non Current Assets
0.00
0.00
-100.00%
0.05
-69.54%
0.17
Net PPE
—
0.00
-100.00%
0.05
-67.88%
0.17
Gross PPE
—
0.00
-100.00%
0.05
-67.88%
0.17
Other Properties
—
—
0.05
-67.88%
0.17
Non Current Prepaid Assets
—
—
0.00
-100.00%
0.01
Total Liabilities Net Minority Interest
2.32
-60.71%
5.90
-11.02%
6.63
+32.61%
5.00
Current Liabilities
2.32
-60.71%
5.90
-11.02%
6.63
+34.33%
4.94
Payables And Accrued Expenses
2.31
-59.15%
5.65
+2.30%
5.52
+14.85%
4.81
Payables
0.75
-80.59%
3.85
-10.98%
4.33
+37.83%
3.14
Accounts Payable
0.75
-80.59%
3.85
-10.98%
4.33
+37.83%
3.14
Current Accrued Expenses
1.56
-13.19%
1.80
+50.38%
1.20
-28.40%
1.67
Current Debt And Capital Lease Obligation
—
—
0.06
-47.27%
0.11
Current Debt
—
—
—
—
Current Capital Lease Obligation
—
0.00
-100.00%
0.06
-47.27%
0.11
Other Current Liabilities
0.01
-95.63%
0.25
-76.05%
1.05
+5436.84%
0.02
Total Non Current Liabilities Net Minority Interest
0.00
0.00
0.00
-100.00%
0.06
Long Term Debt And Capital Lease Obligation
—
—
0.00
-100.00%
0.06
Long Term Capital Lease Obligation
—
—
0.00
-100.00%
0.06
Stockholders Equity
5.79
+446.53%
-1.67
-122.34%
7.48
-36.29%
11.73
Common Stock Equity
5.79
+446.26%
-1.67
-122.35%
7.47
-36.29%
11.73
Capital Stock
0.03
+800.00%
0.00
+50.00%
0.00
-94.12%
0.03
Common Stock
0.03
+1200.00%
0.00
+100.00%
0.00
-96.97%
0.03
Preferred Stock
0.00
+0.00%
0.00
+0.00%
0.00
+0.00%
0.00
Share Issued
25.53
+1042.81%
2.23
+61.83%
1.38
+26.58%
1.09
Ordinary Shares Number
25.53
+1042.81%
2.23
+61.83%
1.38
+26.58%
1.09
Additional Paid In Capital
729.66
+5.21%
693.55
+0.58%
689.54
+0.49%
686.17
Retained Earnings
-723.90
-4.12%
-695.23
-1.93%
-682.07
-1.13%
-674.47
Total Equity Gross Minority Interest
5.79
+446.53%
-1.67
-122.34%
7.48
-36.29%
11.73
Total Capitalization
5.79
+446.53%
-1.67
-122.34%
7.48
-36.29%
11.73
Working Capital
5.79
+446.53%
-1.67
-122.50%
7.42
-36.14%
11.62
Invested Capital
5.79
+446.26%
-1.67
-122.35%
7.47
-36.29%
11.73
Total Debt
—
0.00
-100.00%
0.06
-66.67%
0.17
Capital Lease Obligations
—
0.00
-100.00%
0.06
-66.67%
0.17
Net Tangible Assets
5.79
+446.53%
-1.67
-122.34%
7.48
-36.29%
11.73
Tangible Book Value
5.79
+446.26%
-1.67
-122.35%
7.47
-36.29%
11.73
Interest Payable
—
—
—
—
Line Of Credit
—
—
—
0.00
Preferred Shares Number
0.12
+0.00%
0.12
+0.00%
0.12
+0.00%
0.12
Preferred Stock Equity
0.00
+0.00%
0.00
+0.00%
0.00
+0.00%
0.00
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
-12.91
-0.08%
-12.90
-45.77%
-8.85
+41.83%
-15.22
Cash Flow From Continuing Operating Activities
-12.91
-0.08%
-12.90
-45.77%
-8.85
+41.83%
-15.22
Net Income From Continuing Operations
-28.35
-115.42%
-13.16
-73.25%
-7.60
+63.62%
-20.88
Other Non Cash Items
17.32
—
0.11
-13.85%
0.13
Stock Based Compensation
0.43
+87.83%
0.23
-89.55%
2.20
-71.23%
7.65
Operating Gains Losses
-1.40
-74.38%
-0.80
+85.03%
-5.34
-3462.67%
-0.15
Gain Loss On Investment Securities
-0.20
+75.38%
-0.80
+83.32%
-4.80
-3931.09%
-0.12
Unrealized Gain Loss On Investment Securities
—
0.00
+100.00%
-0.05
-260.00%
0.03
Gain Loss On Sale Of PPE
—
—
0.11
+17.89%
0.10
Change In Working Capital
-0.92
-211.11%
0.83
-57.25%
1.94
+197.39%
-1.99
Change In Prepaid Assets
0.38
+462.50%
-0.10
-395.24%
-0.02
-116.54%
0.13
Change In Payables And Accrued Expense
-1.30
-238.42%
0.94
-52.24%
1.96
+196.65%
-2.03
Change In Accrued Expense
—
—
—
0.00
Change In Payable
—
—
—
-2.03
Change In Account Payable
—
—
—
-2.03
Change In Other Current Assets
0.00
-100.00%
0.05
-52.68%
0.11
+17.89%
0.10
Change In Other Current Liabilities
0.00
+100.00%
-0.06
+50.00%
-0.12
-34.88%
-0.09
Investing Cash Flow
0.00
-100.00%
12.89
+741.76%
-2.01
-116.54%
12.14
Cash Flow From Continuing Investing Activities
0.00
-100.00%
12.89
+741.76%
-2.01
-116.54%
12.14
Net Investment Purchase And Sale
0.00
-100.00%
12.89
+741.76%
-2.01
-116.54%
12.14
Purchase Of Investment
—
—
—
—
Sale Of Investment
0.00
-100.00%
12.89
—
—
Financing Cash Flow
15.78
+430.07%
2.98
-52.52%
6.27
+2898.21%
-0.22
Cash Flow From Continuing Financing Activities
15.78
+430.07%
2.98
-52.52%
6.27
+2898.21%
-0.22
Net Issuance Payments Of Debt
—
—
—
0.00
Issuance Of Debt
—
—
—
0.00
Long Term Debt Issuance
—
—
—
0.00
Net Long Term Debt Issuance
—
—
—
0.00
Net Common Stock Issuance
0.00
-100.00%
2.98
-52.52%
6.27
+2898.21%
-0.22
Common Stock Payments
—
—
0.00
+100.00%
-0.22
Cash Dividends Paid
-0.23
0.00
—
—
Repurchase Of Capital Stock
—
—
0.00
+100.00%
-0.22
Proceeds From Stock Option Exercised
5.50
0.00
—
0.00
Changes In Cash
2.86
-3.51%
2.96
+164.55%
-4.59
-39.35%
-3.30
Beginning Cash Position
4.04
+274.79%
1.08
-80.98%
5.67
-36.75%
8.97
End Cash Position
6.91
+70.75%
4.04
+274.79%
1.08
-80.98%
5.67
Free Cash Flow
-12.91
-0.08%
-12.90
-45.77%
-8.85
+41.83%
-15.22
Interest Paid Supplemental Data
0.00
0.00
-100.00%
0.21
0.00
Income Tax Paid Supplemental Data
0.00
0.00
0.00
0.00
Change In Interest Payable
—
—
—
0.00
Common Stock Issuance
0.00
-100.00%
2.98
-52.52%
6.27
0.00
Issuance Of Capital Stock
10.51
+253.09%
2.98
-52.52%
6.27
0.00
Net Preferred Stock Issuance
10.51
—
—
—
Preferred Stock Dividend Paid
-0.23
0.00
—
—
Preferred Stock Issuance
10.51
—
—
—
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category